Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zatosetron SCHEMBL30949358 | 1.00 | HTR3A (0.51) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| Zatosetron SCHEMBL466401 | 1.00 | HTR3A (0.51) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| Zatosetron SCHEMBL466399 | 1.00 | HTR3A (0.51) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| SCHEMBL8939976 | 0.96 | HTR3A (0.49) | HTR3AMEN1KMT2AHTR4 | |
| Zatosetron SCHEMBL679451 | 0.94 | HTR3A (0.46) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| Zatosetron SCHEMBL635856 | 0.94 | HTR3A (0.46) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| Zatosetron SCHEMBL635857 | 0.94 | HTR3A (0.46) | HTR3AMEN1KMT2AHTR4FFAR4 | |
| SCHEMBL8940096 | 0.90 | MEN1 (0.46) | HTR3AMEN1KMT2AHTR4 | |
| SCHEMBL8940004 | 0.90 | HTR3A (0.49) | HTR3AMEN1KMT2AHTR4 | |
| SCHEMBL8939990 | 0.88 | MEN1 (0.43) | HTR3AMEN1KMT2AHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692084-A1 | NOVEL DERIVATIVES OF N-SUBSTITUTED NORTROPINONE, THEIR PRODUCTION AND THEIR USE | Siegfried AG (CH) | 2026-02-11 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3691637-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE Pharmaceuticals GmbH (AT) | 2020-08-12 | — | — | EP | claimed |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2020-08-06 | — | — | US | claimed |
| CN-111201019-A | Oral bendamustine formulations | 图贝药物有限公司 | 2020-05-26 | — | — | CN | claimed |
| EP-1077704-A1 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000045817-A1 | DRUG COMBINATIONS COMPRISING (E) -7 - [4 -(4 -FLUOROPHENYL) -6 - ISOPROPYL -2 - [METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN -5 -YL] (3R,5S) -3,5 - DIHYDROXYHEPT -6 - ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| WO-1999059593-A1 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1997047285-A1 | GASTRIC-RETENTIVE ORAL CONTROLLED DRUG DELIVERY SYSTEM WITH ENHANCED RETENTION PROPERTIES | DEPOMED, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | claimed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | claimed |
| EP-0650355-A1 | MEDICAMENTS FOR THE TREATMENT OF VISCERAL PAIN AND MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1995-05-03 | — | — | EP | claimed |
| WO-1994001095-A2 | MEDICAMENTS FOR THE TREATMENT OF VISCERAL PAIN AND MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1994-01-20 | — | — | WO | claimed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR3A 143/4885MEN1 414/4885KMT2A 4022/4885 |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | ABCB1, MTHFD1, BHMT | HTR3A 3119/4885MEN1 2036/4885KMT2A 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.